Skip to content

Semaglutide

Sold under the brand names; Wegovy & Ozempic and approved for use (depending on the brand) for weight management, blood glucose management and cardiovascular risk reduction.

Semaglutide binds to, and activates, the GLP-1 (glucagon-like peptide-1) receptor to increase insulin secretion, suppress glucagon secretion, and slow gastric emptying.1

Key Usage Considerations

Oral vs Injectable Treatment

Body Composition

Exercise is better for this.

Side Effects

Ending Treatment

  1. https://bnf.nice.org.uk/drugs/semaglutide/ - 2024-12-04 ↩